

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) fo

New England Journal of Medicine

386, 2188-2200

DOI: 10.1056/nejmoa2116620

Citation Report

#	ARTICLE	IF	CITATIONS
1	A living WHO guideline on drugs to prevent covid-19. <i>BMJ, The</i> , 2021, 372, n526.	3.0	73
2	Prophylaxis against covid-19: living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 373, n949.	3.0	78
5	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
6	Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. <i>Cancer Cell</i> , 2022, 40, 590-591.	7.7	70
7	Human Identical Sequences, hyaluronan, and hymecromone – the new – mechanism and management of COVID-19. <i>Molecular Biomedicine</i> , 2022, 3, 15.	1.7	4
9	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 176-188.	1.8	7
10	Efficacy of anti – SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. <i>Kidney International</i> , 2022, 102, 440-442.	2.6	36
12	Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6083.	1.8	10
13	Multiple Autoimmune Syndromes Including Acute Disseminated Encephalomyelitis, Myasthenia Gravis, and Thyroiditis Following Messenger Ribonucleic Acid-Based COVID-19 Vaccination: A Case Report. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	11
14	A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies. <i>Current Oncology</i> , 2022, 29, 3940-3949.	0.9	7
17	Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103905.	0.9	21
18	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	20
19	Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19. <i>New England Journal of Medicine</i> , 2022, 386, 2236-2238.	13.9	3
20	Efficacy and safety of intramuscular administration of tixagevimab – cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 985-996.	5.2	132
21	Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. <i>American Journal of Transplantation</i> , 2022, 22, 3130-3136.	2.6	85
22	Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	14
23	Tixagevimab + Cilgavimab: First Approval. <i>Drugs</i> , 2022, 82, 1001-1010.	4.9	31
24	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8

#	ARTICLE	IF	CITATIONS
25	Lessons from SARS-CoV-2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	5
26	Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1824-1829.	0.4	6
27	Early treatment to prevent progression of SARS-CoV-2 infection. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 930-931.	5.2	11
29	COVID-19 and the Functionality of Antivirals: The Day After Tomorrow. <i>Health Security</i> , 2022, 20, 270-271.	0.9	0
30	Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. <i>Journal of Autoimmunity</i> , 2022, 131, 102848.	3.0	10
31	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	0.6	20
32	COVID antibody drugs have saved lives – so why aren't they more popular?. <i>Nature</i> , 2022, 606, 854-856.	13.7	4
33	An Executed Plan to Combat COVID-19 in the United States. <i>Advances in Anesthesia</i> , 2022, 40, 45-62.	0.5	1
34	Stewardship of COVID-19 volunteers by nested trial design. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1400-1401.	4.6	1
35	Immunity to a third BNT162B2 COVID-19 vaccine after heart transplantation: bridging the knowledge gap to end the pandemic for organ transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2022, , .	0.3	3
36	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. <i>Cell Host and Microbe</i> , 2022, 30, 1231-1241.e6.	5.1	55
37	Monoclonal antibody therapies against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e311-e326.	4.6	114
38	Reply to the letter – Effectiveness of COVID-19 vaccines against Omicron variant. <i>Immunotherapy</i> , 2022, 14, 905-908.	1.0	3
39	Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (<sc>AZD7442</sc>) Administered Intravenously Versus Intramuscularly in Symptomatic <sc>SARS-CoV</sc>-2 Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1207-1213.	2.3	8
42	Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 280-287.	1.3	6
43	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1477-1488.	1.3	28
44	COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders. <i>Kidney International</i> , 2022, 102, 936-938.	2.6	29
45	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. <i>Cancers</i> , 2022, 14, 3598.	1.7	7

#	ARTICLE	IF	CITATIONS
46	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
47	Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
48	Managing COVID-19 in pregnant women. <i>Breathe</i> , 2022, 18, 220019.	0.6	0
49	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. <i>Cancers</i> , 2022, 14, 3711.	1.7	6
50	Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2688-2692.	1.3	16
51	Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1594-1602.	0.5	22
52	Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality. <i>Clinical Infectious Diseases</i> , 2023, 76, e126-e132.	2.9	48
53	Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
54	A rapid decline in the anti-â€œreceptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab-â€œcilgavimab administration. <i>Kidney International</i> , 2022, 102, 1188-1190.	2.6	8
55	Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. <i>Pathogens</i> , 2022, 11, 882.	1.2	7
56	Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre-â€œexposure prophylaxis of COVID-19: A case series. <i>Transplant Infectious Disease</i> , 0, , .	0.7	5
57	Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?. <i>Viruses</i> , 2022, 14, 1860.	1.5	0
58	European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1578-1590.	2.8	9
61	Solid Organ Rejection following SARS-CoV-2 Vaccination or COVID-19 Infection: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 1289.	2.1	16
62	Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic. <i>Current Infectious Disease Reports</i> , 2022, 24, 129-145.	1.3	17
63	Monoclonal Antibodies â€œ A Different Approach to Combat Malaria. <i>New England Journal of Medicine</i> , 2022, 387, 460-461.	13.9	3
64	Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1742-1749.	0.5	26
65	The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era. <i>Arthritis and Rheumatology</i> , 2022, 74, 1868-1871.	2.9	0

#	ARTICLE	IF	CITATIONS
66	Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2. <i>Structural Chemistry</i> , 2022, 33, 1585-1608.	1.0	6
67	Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101375.	0.7	0
68	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. <i>3 Biotech</i> , 2022, 12, .	1.1	4
69	Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
70	Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. <i>IScience</i> , 2022, 25, 104935.	1.9	8
71	A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheldâ,©) for COVID-19 Prophylaxis and Treatment. <i>Viruses</i> , 2022, 14, 1999.	1.5	34
72	EXABS-181-CLL Infection Prophylaxis in Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S83-S84.	0.2	0
73	Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients. <i>EClinicalMedicine</i> , 2022, 53, 101642.	3.2	32
74	COVID-19 treatments. <i>LymphoSign Journal</i> , 2022, 9, 57-61.	0.1	1
75	Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients. <i>Kidney International Reports</i> , 2022, 7, 2537-2538.	0.4	15
76	The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis. <i>Journal of Infection</i> , 2023, 86, e15-e17.	1.7	6
77	Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis. <i>Biomedicines</i> , 2022, 10, 2150.	1.4	8
78	Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. <i>RMD Open</i> , 2022, 8, e002557.	1.8	22
79	The Prevention of COVID-19 in High-Risk Patients Using Tixagevimabâ€Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center. <i>American Journal of Medicine</i> , 2023, 136, 96-99.	0.6	26
81	Immunogenicity of two doses of <sc>BNT162b2</sc> and <sc>mRNA</sc>â€1273 vaccines for solid cancer patients on treatment with or without a previous <sc>SARSâ€CoV</sc>â€2 infection. <i>International Journal of Cancer</i> , 2023, 152, 661-671.	2.3	3
82	Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). <i>Transplantation and Cellular Therapy</i> , 2022, 28, 810-821.	0.6	9
84	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021â€2022. <i>Jammi</i> , 2022, 7, 163-169.	0.3	0
85	Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6

#	ARTICLE	IF	CITATIONS
86	Reappraisal of Coronavirus Disease 2019 Risk for Patients With Inflammatory Bowel Disease: Withdrawal of the British Society of Gastroenterology Inflammatory Bowel Disease Risk Grid. <i>Gastroenterology</i> , 2023, 164, 2-4.	0.6	0
87	SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101384.	0.7	6
88	Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study. <i>Journal of Infection</i> , 2022, 85, 545-556.	1.7	20
89	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	2.9	82
90	Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab. <i>Journal of Clinical Rheumatology</i> , 2023, 29, 109-111.	0.5	21
91	Care for adults with <scp>COVID</scp> â€19: living guidelines from the National <scp>COVID</scp> â€19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378.	0.8	8
92	SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> , 2022, 55, 1779-1798.	6.6	50
93	Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution. <i>Journal of Infectious Diseases</i> , 2022, 226, 1913-1923.	1.9	19
94	Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-17.	0.5	2
95	Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1397.	0.8	5
96	DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	5.8	15
97	An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1695-1700.	0.9	1
98	Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation. <i>Journal of Infection</i> , 2023, 86, 66-117.	1.7	5
99	Is standby therapy for Covid-19 a practical option for travellers?. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	1
101	SARS-CoV-2 vaccine strategies in kidney transplant recipients. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 263-264.	4.6	3
102	Long COVID: An inevitable sequela of SARS-CoV-2 infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 1-9.	1.5	42
103	Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. <i>RMD Open</i> , 2022, 8, e002575.	1.8	3
104	COVID-19 Treatmentâ€”Current Status, Advances, and Gap. <i>Pathogens</i> , 2022, 11, 1201.	1.2	7

#	ARTICLE	IF	CITATIONS
105	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. <i>Life</i> , 2022, 12, 1605.	1.1	12
106	Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. <i>Current Pharmaceutical Design</i> , 2022, 28, 3658-3670.	0.9	3
107	SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. <i>Hematological Oncology</i> , 2023, 41, 128-138.	0.8	6
108	A Review of Potential Therapeutic Strategies for COVID-19. <i>Viruses</i> , 2022, 14, 2346.	1.5	3
109	SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
111	Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis. <i>Clinical Infectious Diseases</i> , 2023, 76, 1067-1073.	2.9	18
112	COVID-19 and HSCT (Hematopoietic stem cell transplant). <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101399.	0.7	8
113	Medications for early treatment of COVID-19 in Australia. <i>Medical Journal of Australia</i> , 0, , .	0.8	0
114	Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance – VISION Network, 10 States, December 2021–August 2022. <i>Morbidity and Mortality Weekly Report</i> , 2022, 71, 1335-1342.	9.0	54
115	Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 307-319.	4.6	31
116	Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination. <i>Analytical Chemistry</i> , 2022, 94, 14835-14845.	3.2	6
117	SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients – A Single-Center Experience. <i>Viruses</i> , 2022, 14, 2278.	1.5	10
118	Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations. <i>Hematological Oncology</i> , 2023, 41, 3-15.	0.8	7
119	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
120	Monoclonal antibodies for the treatment of COVID-19 infection in children. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1529-1535.	2.0	1
121	Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. <i>Expert Review of Anti-Infective Therapy</i> , 0, , 1-11.	2.0	3
122	COVID-19 Therapeutics and Considerations for Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, , .	0.7	0
123	Vaccination efficacy in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2023, 64, 42-56.	0.6	3

#	ARTICLE	IF	CITATIONS
124	Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study. <i>American Journal of Hematology</i> , 2023, 98, 102-111.	2.0	9
125	Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era. <i>Viruses</i> , 2022, 14, 2377.	1.5	16
126	Recent review of COVID-19 management: diagnosis, treatment and vaccination. <i>Pharmacological Reports</i> , 2022, 74, 1120-1148.	1.5	37
127	What Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the Topic. <i>Transplantology</i> , 2022, 3, 288-306.	0.3	0
128	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
129	Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection. <i>Aids</i> , 2022, 36, 2171-2179.	1.0	13
130	Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies. <i>Nature Communications</i> , 2022, 13, .	5.8	9
132	Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis against COVID-19: a population-based propensity-matched cohort study. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	8
133	Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100850.	3.3	32
135	Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 0, , .	1.2	3
136	Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. <i>Blood</i> , 2023, 141, 200-203.	0.6	33
137	Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. <i>HemaSphere</i> , 2022, 6, e807.	1.2	1
138	Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario. <i>Cancers</i> , 2022, 14, 5512.	1.7	6
140	Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 22-23.	4.6	103
142	Cardiac and vascular serious adverse events following tixagevimab-cilgavimab Author's reply. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, e7-e8.	5.2	4
143	Cardiac and vascular serious adverse events following tixagevimab-cilgavimab. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, e5-e6.	5.2	7
144	COVID-19 in Patients with Hematologic Diseases. <i>Biomedicines</i> , 2022, 10, 3069.	1.4	3
145	The Promise and Peril of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Monoclonal Antibodies. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1

#	ARTICLE	IF	CITATIONS
146	Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells. <i>Viruses</i> , 2022, 14, 2620.	1.5	1
147	COVID-19 Vaccines: An Updated Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 714.	1.6	11
148	AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2023, 76, 1247-1256.	2.9	16
149	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. <i>Science China Life Sciences</i> , 2023, 66, 658-678.	2.3	3
150	Antiviral Treatment of COVID-19 Pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
151	Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	22
152	Structural insights into the rational design of a nanobody that binds with high affinity to the SARS-CoV-2 spike variant. <i>Journal of Biochemistry</i> , 2023, 173, 115-127.	0.9	3
153	Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?. <i>Clinical Infectious Diseases</i> , 2022, 75, S530-S540.	2.9	4
155	Public Interest in COVID-19 Therapeutics for High-Risk Populations During the Omicron Era: A Google Trends Analysis. <i>Cureus</i> , 2022, , .	0.2	2
156	Increased reporting of venous and arterial thromboembolic events reported with tixagevimab+cilgavimab for coronavirus disease 2019. <i>Clinical Microbiology and Infection</i> , 2023, 29, 543.e1-543.e3.	2.8	4
158	Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 118.	1.0	11
160	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
161	Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	11
162	Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays. <i>American Journal of Clinical Pathology</i> , 0, , .	0.4	0
163	Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 6198-6207.	2.5	9
164	Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies. <i>MABs</i> , 2023, 15, .	2.6	3
165	AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. <i>Cell Reports Medicine</i> , 2023, 4, 100882.	3.3	10
166	A molecular understanding of alphavirus entry and antibody protection. <i>Nature Reviews Microbiology</i> , 2023, 21, 396-407.	13.6	9

#	ARTICLE	IF	CITATIONS
167	FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. <i>Nature</i> , 2023, 615, 134-142.	13.7	131
168	Treating asthma in the time of COVID. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 809-817.	1.5	1
169	Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19. <i>Microorganisms</i> , 2022, 10, 2490.	1.6	1
170	Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies. <i>Blood Advances</i> , 2023, 7, 2459-2462.	2.5	8
171	WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?. <i>Life</i> , 2023, 13, 134.	1.1	3
172	HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049.	0.8	2
173	Learning how to treat coronavirus disease 2019 in hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	0
174	COVID-19 prophylaxis: half-full or half-empty glass?. <i>Blood</i> , 2023, 141, 130-132.	0.6	1
175	A Multidisciplinary Approach to Managing BTK Inhibitor Toxicity in Lymphoma and Chronic Lymphocytic Leukemia. , 2023, , .		1
176	Efficacy and safety of tixagevimab+cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	17
178	A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19). <i>Antibodies</i> , 2023, 12, 5.	1.2	15
179	Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 231-245.	2.5	4
180	Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. <i>Clinical Transplantation</i> , 2023, 37, .	0.8	4
181	Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients. <i>American Journal of Transplantation</i> , 2023, 23, 423-428.	2.6	8
182	Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study. <i>Journal of Clinical Virology</i> , 2023, 159, 105374.	1.6	3
183	Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 70, 104484.	0.9	11
184	Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. <i>Viruses</i> , 2023, 15, 118.	1.5	18
186	Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 326-344.	0.1	0

#	ARTICLE	IF	CITATIONS
187	Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer. <i>JAMA Oncology</i> , 2023, 9, 386.	3.4	23
188	Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern. <i>Viruses</i> , 2023, 15, 139.	1.5	8
189	Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 210-215.	0.4	11
190	Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms. <i>Infection and Drug Resistance</i> , 0, Volume 16, 509-519.	1.1	3
191	Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	1.3	1
192	Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2023, 227, 1153-1163.	1.9	4
193	SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients. <i>Transplant International</i> , 0, 36, .	0.8	1
194	Recurrent Acute Disseminated Encephalomyelitis (ADEM) after COVID-19-vaccination and after subsequent COVID-19-infection: A case report (part II). <i>Frontiers in Neurology</i> , 0, 14, .	1.1	2
195	Mycophenolic Acid Exposure Determines Antibody Formation Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 118-126.	2.3	4
196	Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections. <i>Expert Review of Hematology</i> , 2023, 16, 267-276.	1.0	0
197	COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma. <i>MBio</i> , 0, , .	1.8	1
198	Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients: A Prospective Cohort Study. <i>Vaccines</i> , 2023, 11, 799.	2.1	0
199	Vaccines and therapeutics for immunocompromised patients with COVID-19. <i>EClinicalMedicine</i> , 2023, 59, 101965.	3.2	28
200	Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 209-228.	0.7	1
201	Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. <i>Blood Advances</i> , 2023, 7, 5691-5697.	2.5	4
202	Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis. <i>Journal of Clinical Virology</i> , 2023, 160, 105382.	1.6	6
203	The Effectiveness of COVID -19 Vaccine for Immunocompromised Adults During Omicron Predominance. <i>Archives of Clinical Infectious Diseases</i> , 2023, 17, .	0.1	0
204	Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 101-107.	1.3	6

#	ARTICLE	IF	CITATIONS
205	Tixagevimab and Cilgavimab (Evusheldâ„†) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study. <i>Vaccines</i> , 2023, 11, 350.	2.1	6
206	A beacon in the dark: COVID-19 course in COVID patients from two European countries: Different approaches, similar outcomes. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
207	Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	0
208	Cross-protective antibodies against common endemic respiratory viruses. <i>Nature Communications</i> , 2023, 14, .	5.8	6
209	Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <i>Nature Communications</i> , 2023, 14, .	5.8	87
210	Current and Emerging Therapies for COVID-19 in Lung Transplantation. <i>Current Pulmonology Reports</i> , 2023, 12, 23-35.	0.5	1
211	Dynamics of antibody titers to SARS-CoV-2 and clinical outcomes after sotrovimab pre-exposure prophylaxis early after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	0
212	A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma. <i>International Journal of Hematology</i> , 2023, 117, 900-909.	0.7	1
213	Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1
215	Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study. <i>Vaccines</i> , 2023, 11, 493.	2.1	0
216	Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
217	Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents. <i>British Journal of Haematology</i> , 2023, 201, 564-567.	1.2	4
218	Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19. <i>Terapevticheskii Arkhiv</i> , 2023, 95, 66-77.	0.2	0
219	Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID. <i>Viruses</i> , 2023, 15, 614.	1.5	0
220	Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies. <i>Terapevticheskii Arkhiv</i> , 2023, 95, 78-84.	0.2	3
221	Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	3
222	Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms. <i>Annals of Hematology</i> , 2023, 102, 819-827.	0.8	2
223	Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9

#	ARTICLE	IF	CITATIONS
224	Characteristics of COVID-19 vaccinated and unvaccinated patients admitted to Careggi University Hospital, Florence, Italy. <i>Internal and Emergency Medicine</i> , 2023, 18, 821-830.	1.0	2
225	Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity. <i>Journal of Clinical Immunology</i> , 2023, 43, 865-868.	2.0	2
226	Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
227	Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG). <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.4	1
229	Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. <i>EClinicalMedicine</i> , 2023, 57, 101898.	3.2	1
230	Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 695-711.	0.8	0
231	Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. <i>Expert Review of Vaccines</i> , 2023, 22, 341-365.	2.0	4
232	Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand. <i>Applied Health Economics and Health Policy</i> , 2023, 21, 511-522.	1.0	1
233	Protein-protein interactions in solutions of monoclonal antibodies probed by the dependence of the high-frequency viscosity on temperature and concentration. <i>Analyst</i> , The, 2023, 148, 1887-1897.	1.7	0
235	RE: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS). <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
236	COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence. <i>Infectious Disease Clinics of North America</i> , 2023, , .	1.9	1
237	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
239	The COVID-19 Pandemic and Adult Cardiac Transplantation: Impact, Interventions, and Implications. <i>Canadian Journal of Cardiology</i> , 2023, 39, 853-864.	0.8	1
241	Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era. <i>Infection</i> , 2023, 51, 1481-1489.	2.3	5
242	Response to Song. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	0
243	Conference proceedings from hybrid 25th Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 0, , .	0.9	0
244	Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2023, 77, 280-286.	2.9	40
245	Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	1

#	ARTICLE	IF	CITATIONS
246	Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
247	Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). <i>Applied Sciences (Switzerland)</i> , 2023, 13, 4471.	1.3	1
248	Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	10
249	Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. <i>British Journal of Haematology</i> , 2023, 201, 813-823.	1.2	7
250	COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. <i>Biology</i> , 2023, 12, 545.	1.3	2
251	Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab/cilgavimab. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 528-530.	4.6	7
252	Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	4
253	SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
254	Central Nervous System Neuroimmunologic Complications of COVID-19. <i>Seminars in Neurology</i> , 0, , .	0.5	0
255	Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use. <i>Viruses</i> , 2023, 15, 1025.	1.5	6
281	Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	1
308	Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 27-49.	0.8	0
321	Pharmacological and Non-pharmacological Intervention in Epidemic Prevention and Control: A Medical Perspective. <i>Lecture Notes on Data Engineering and Communications Technologies</i> , 2023, , 573-582.	0.5	0
386	Passive antibody therapy in emerging infectious diseases. <i>Frontiers of Medicine</i> , 2023, 17, 1117-1134.	1.5	2
387	TO MARKET, TO MARKET—2022: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 713-798.	0.1	0
390	Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
399	Management of Immunosuppressed Dermatology Patients During COVID-19. <i>Updates in Clinical Dermatology</i> , 2023, , 109-120.	0.1	0
409	Clinical course and management of COVID-19 in the era of widespread population immunity. <i>Nature Reviews Microbiology</i> , 2024, 22, 75-88.	13.6	1

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------